Pharmacogenetics: Pharmacokinetics and clinical implications;Farmacogenetica: Farmacocinetica ed implicazioni cliniche

Recenti Progressi in Medicina

Volumn 88, Issue 1, 1997, Pages 46-55

  Blardi, Patrizia ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

cytochrome P 450; pharmacodynamic; pharmacogenetics; pharmacokinetics

Indexed keywords

ALPRENOLOL; AMITRIPTYLINE; AMRINONE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUFURALOL; CAFFEINE; CLONAZEPAM; CODEINE; CYTOCHROME P450; DAPSONE; ENCAINIDE; FLECAINIDE; HYDRALAZINE; IMIPRAMINE; INDORAMIN; ISONIAZID; MEPHENYTOIN; METOPROLOL; NITRAZEPAM; PHENFORMIN; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; SALAZOSULFAPYRIDINE; SULFAMERAZINE; TIMOLOL; UNINDEXED DRUG;

ACETYLATION; DRUG ELIMINATION; DRUG METABOLISM; DRUG OXIDATION; GENETIC POLYMORPHISM; HUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOKINETICS; REVIEW;

ACETYLATION; CLINICAL TRIALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG TOXICITY; FEMALE; HUMANS; MALE; METABOLISM, INBORN ERRORS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHARMACOKINETICS; PHENOTYPE;

EID: 0031041444     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Vogel F. Moderne Probleme der Humangenetik. Ergeb Inn Med Kinderheilk 1959; 12: 52-125.
2. Gunnar A. Genetic polymorphisms in drug metabolism. J Int Med 1982; 231: 571-3.
3. Brosen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 1990; 18: 220-39.
4. Nebert DW, Nelson DR, Coon MJ et al. The P450 super family: update on new sequence, gene mapping, and recommended nomenclature. DNA Cell Biol 1991; 10: 1-14.
5. Gonzalez FJ. Molecular genetics of the P450 superfamily. Pharmacol Ther 1990; 45: 1-38.
6. Otton SV et al. Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. Life Sciences 1984; 34: 73.
7. Inaba T et al. In vitro inhibition studies of two isozymes of human liver cytochrome P450, mephenytoin p-hydroxylase and sparteine mono-oxygenase. Drug Metab Dispos 1985; 13: 443.
8. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; ii: 584-6.
9. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16: 183-7.
10. Lledò P. Variations in drug metabolism due to genetic polymorphism. A review of the debrisoquine/sparteine type. Drug Invest 1993; 5: 19-34.
11. Dayer P, Kubli A, Kupfer A, Courvoisier F, Balant L, Fabre J. Defective hydroxilation of bufuralol associated with side-effects of the drug in poor metabolisers. Br J Clin Pharmac 1982; 13: 750-2.
12. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF. Oxidation phenotype-major determinant of metoprolol metabolism and response. New Engl J Med 1982; 307: 1558-60.
13. Lennard MS, Silas JH, Freestone S, Trevethick J. Defective metabolism of metoprolol in poor metabolisers of debrisoquine. Br J Clin Pharmac 1982; 14: 301-3.
14. McGourty JC, Silas JH, Lennard MS, Tucker GT, Woods HF. Metoprolol metabolism and debrisoquine oxidation polymorphism-population and family studies. Br J Clin Pharmac 1985; 20: 555-66.
15. Lennard MS, Lewis RV, Brawn LA et al. Timolol metabolism and debrisoquine oxidation polymorphism: a population study. Br J Clin Pharmac 1989; 27: 429-34.
16. Lennard MS et al. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol. Br J Clin Pharmacol 1984; 17: 679-85.
17. Siddoway LA, Thompson KA, McAllister CB et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987; 75: 785-91.
18. Lee JT, Kroemer HK, Silberstein DJ et al. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med 1990; 322: 1764-8.
19. Wang T et al. Influence of genetic polymorphism on the metabolism and disposition of encainide in man. J Pharmacol Exp Ther 1984; 228: 605.
20. Funck-Brentano C et al. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. J Pharmacol Exp Ther 1989; 249: 134.
21. Funck-Brentano C. Polymorphisme génétique du métabolisme des médicaments utilisés en pathologie cardiovasculaire. Arch Mal Coeur 1991; 84: 1353-9.
22. Kupfer A et al. Family study of a genetically determined deficiency of mephenytoin hydroxylation in man. Pharmacologist 1979; 21: 173.
23. Grant DM et al. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 1991; 39: 184.
24. Mitchell RS, Bell JC. Clinical implications of isoniazid blood levels in pulmonary tuberculosis. N Engl J Med 1957; 1068-70.
25. Prince Evans DA, Manley KA, McKusick VA. Genetic controlof isoniazid metabolism in man. Brit Med J 1960; 485-91.
26. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985; 37: 25.
27. Evans DAP, White TA. Human acetylation polymorphism. J Lab Clin Med 1964; 63: 395.
28. Hamilton RA et al. Effect of the acetylator phenotype on amrinone pharmacokinetics. Clin Pharmacol Ther 1986; 40: 615.
29. Ramsay LE, Silas JH, OllerenshawJD, Tucker GT, Phillips FC, Freestone S. Shouhld the acetylator phenotype be determined when prescibing hydralazine for hypertension? Eur J Clin Pharmacol 1984; 26: 39-42.
30. Lima JJ, Conti DR, Goldfarb AL, Tilstone WJ, Golden LH, Jusko WJ. Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype. J Pharmacokinet Biopharmaceutics 1979; 7: 69-85.
31. Kupfer A et al. Family study of genetically determined deficiency of mephenytion hydroxylation in man. Pharmacologist 1979; 21: 173.
32. Evans DAP. N-acetyltransferase. Pharmacol Ther 1989; 42: 157.
33. Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Int Med 1986; 105: 179-84.
34. Mansilla-Tinoco R, Harland SJ, Ryan PJ et al. Hydralazine, antinuclear antibodies, and the lupus syndrome. Br Med J 1982; 284: 936-9.
35. Weinshilboum RM. Methylation pharmacagenetics: thiopurine methyltransferase as a model system. Xenobiotica 1992; 22: 1055-71.
36. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Childhood acute lymphoblastic leukaemia: pharmacogenetic variation in response to 6-mercaptopurine. Lancet 1990; 336: 225-9.
37. Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmac Ther 1987; 41: 18-25.
38. Lennard L, Van Loon J, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmac Ther 1989; 46:149-54.